Success Stories

Talent Biotechs

Innovative Cannabidiol-based treatments.
Talent is a clinical phase company recently acquired by Kalytera Therapeutics (TSXV: KALY). Talent developed CBD-based drugs for the prevention and treatment of GVHD. The company showed very promising results in four phase 2a trials at Beilinson Medical Center.

GvHD is a multisystem disorder that is a common, life-threatening complication of hematopoietic stem cell transplant (“HCT”) procedures. GvHD occurs when the transplanted donor cells attack the patient’s organs, including the skin, gastrointestinal tract, liver, lungs, and eyes.

Program Highlights

 

 Four Phase 2a clinical trials complete, one published study demonstrating proof-of-concept
  • Orphan Drug Designation (“ODD”) granted in U.S. and Europe
  • Urgent unmet need; there are currently no FDA approved therapies for the prevention or treatment of GvHD in its acute and chronic forms

 

https://kalytera.co/

Talent Biotechs
Share this Page:
Facebook Twitter Google LinkedIn Email